[Systemic Therapy of Metastatic Colorectal Cancer].

[Systemic Therapy of Metastatic Colorectal Cancer]. Zentralbl Chir. 2019 Jun;144(3):252-258 Authors: Modest DP, von Bergwelt M Abstract The successful management of metastatic colorectal cancer (mCRC) is an interdisciplinary challenge, involving medical oncology, surgery and also interventional specialists. Systemic therapy of mCRC is based on regimens of chemotherapeutic combinations plus monoclonal antibodies targeting EGFR and VEGF. EGFR-directed antibodies can guided by biomarkers, namely RAS mutation and sidedness of the primary tumor. In pretreated patients, several targetable molecular markers (i.e. BRAF mutation, MSI-status and Her2) should be tested. BRAF inhibitors, checkpoint-inhibitors and her2-targeted combinations (although off-label therapy) increase the available therapeutic options in these selected subgroups. PMID: 31167268 [PubMed - in process]
Source: Zentralblatt fur Chirurgie - Category: Surgery Authors: Tags: Zentralbl Chir Source Type: research